SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
January 1, 2013
Date of Report (Date of earliest event reported)
Nano Mask, Inc.
(Exact name of registrant as specified in its charter)
Registrant's telephone number, including area code
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Nano Mask, Inc. (the Company) has appointed Dr. Hassan Bennani to its board of directors. Dr. Bennani is the co-founder and CEO of KellBenx, Incorporated, a closely held Long Island, NY based biotechnology company focused on women's healthcare, concentrating on the development of a patented breakthrough non-invasive prenatal diagnostic (NIPD) for analyzing genetic disorders and a patent pending breakthrough test to determine a woman's risk of preterm delivery.
Dr. Bennani was previously the head of business development at Lenetix, a women's health focused lab acquired by Bio-Reference Laboratories. Prior to that, Dr. Bennani was a Vice President of Sales and Marketing for Adeza Biomedical Corporation, which was acquired by Hologic.
There is no arrangement or understanding with any other person pursuant to which Dr. Bennani was appointed. Dr. Bennani will be entitled to compensation as a non-employee director pursuant to the Companys current non-employee director compensation policy at an annual rate of $15,000. The board has not yet determined a committee assignment for Dr. Bennani.
A press release announcing the board appointment is attached to this filing as an exhibit.
Item 9.01 Financial Statements and Exhibits
Ex 99 Press release dated January 24, 2013
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATED: January 24, 2013
Nano Mask, Inc.
By: /S/ Edward J. Suydam
Edward Suydam, CEO and President